Published in J Virol on October 01, 2001
Human parechovirus 3 and neonatal infections. Emerg Infect Dis (2005) 2.02
Analysis of a new human parechovirus allows the definition of parechovirus types and the identification of RNA structural domains. J Virol (2006) 1.87
Isolation and characterization of novel human parechovirus from clinical samples. Emerg Infect Dis (2007) 1.68
Picornaviruses. Curr Top Microbiol Immunol (2010) 1.53
Novel human parechovirus from Brazil. Emerg Infect Dis (2009) 1.36
Human parechovirus type 1, 3, 4, 5, and 6 detection in picornavirus cultures. J Clin Microbiol (2007) 1.28
Integrin alpha v beta 6 is an RGD-dependent receptor for coxsackievirus A9. J Virol (2004) 1.16
Prevalence of human parechovirus in the Netherlands in 2000 to 2007. J Clin Microbiol (2008) 1.09
Identification of a contemporary human parechovirus type 1 by VIDISCA and characterisation of its full genome. Virol J (2008) 1.01
Interaction of alphaVbeta3 and alphaVbeta6 integrins with human parechovirus 1. J Virol (2010) 0.99
Human parechovirus infection in children hospitalized with acute gastroenteritis in Sri Lanka. J Clin Microbiol (2010) 0.88
The Structure of Human Parechovirus 1 Reveals an Association of the RNA Genome with the Capsid. J Virol (2015) 0.86
Novel human parechovirus, Sri Lanka. Emerg Infect Dis (2010) 0.85
Structural Basis of Human Parechovirus Neutralization by Human Monoclonal Antibodies. J Virol (2015) 0.84
Identification of a conserved B-cell epitope on duck hepatitis A type 1 virus VP1 protein. PLoS One (2015) 0.82
Endocytosis of integrin-binding human picornaviruses. Adv Virol (2012) 0.82
High pressure processing and its application to the challenge of virus-contaminated foods. Food Environ Virol (2012) 0.81
Identification and characterization of two strains of human parechovirus 4 isolated from two clinical cases in Fukuoka City, Japan. J Clin Microbiol (2008) 0.80
Human Memory B Cells Producing Potent Cross-Neutralizing Antibodies against Human Parechovirus: Implications for Prevalence, Treatment, and Diagnosis. J Virol (2015) 0.79
Human parechovirus genotypes -10, -13 and -15 in Pakistani children with acute dehydrating gastroenteritis. PLoS One (2013) 0.79
Virion Structure of Iflavirus Slow Bee Paralysis Virus at 2.6-Angstrom Resolution. J Virol (2016) 0.78
Genome and infection characteristics of human parechovirus type 1: the interplay between viral infection and type I interferon antiviral system. PLoS One (2015) 0.77
Role of Heparan Sulfate in Cellular Infection of Integrin-Binding Coxsackievirus A9 and Human Parechovirus 1 Isolates. PLoS One (2016) 0.76
Human Parechovirus 1 Infection Occurs via αVβ1 Integrin. PLoS One (2016) 0.75
Structure of deformed wing virus, a major honey bee pathogen. Proc Natl Acad Sci U S A (2017) 0.75
Integrins: versatility, modulation, and signaling in cell adhesion. Cell (1992) 34.06
New perspectives in cell adhesion: RGD and integrins. Science (1987) 18.41
Nucleotide sequence and genome organization of foot-and-mouth disease virus. Nucleic Acids Res (1984) 3.81
The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol (1989) 3.53
A distinct picornavirus group identified by sequence analysis. Proc Natl Acad Sci U S A (1992) 3.28
Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J Virol (1996) 3.12
Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J Virol (1995) 2.66
The nucleotide sequence of coxsackievirus A9; implications for receptor binding and enterovirus classification. J Gen Virol (1989) 2.52
RGD sequence of foot-and-mouth disease virus is essential for infecting cells via the natural receptor but can be bypassed by an antibody-dependent enhancement pathway. Proc Natl Acad Sci U S A (1994) 2.49
The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J (1999) 2.28
Molecular and biological characteristics of echovirus 22, a representative of a new picornavirus group. J Virol (1994) 2.27
The epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus. J Virol (2000) 2.24
Human parechoviruses--biology and clinical significance. Rev Med Virol (2000) 2.24
Structure, function and evolution of picornaviruses. J Gen Virol (1990) 2.17
The 2A proteins of three diverse picornaviruses are related to each other and to the H-rev107 family of proteins involved in the control of cell proliferation. J Gen Virol (2000) 1.96
Entry of coxsackievirus A9 into host cells: specific interactions with alpha v beta 3 integrin, the vitronectin receptor. Virology (1994) 1.96
RGD-dependent entry of coxsackievirus A9 into host cells and its bypass after cleavage of VP1 protein by intestinal proteases. J Virol (1991) 1.91
Virus-encoded proteinases of the picornavirus super-group. J Gen Virol (1997) 1.86
Molecular analysis of human parechovirus type 2 (formerly echovirus 23). J Gen Virol (1998) 1.84
Foot-and-mouth disease virus virulent for cattle utilizes the integrin alpha(v)beta3 as its receptor. J Virol (1998) 1.83
Diagnosis and epidemiology of echovirus 22 infections. Clin Infect Dis (1998) 1.74
Complete sequence of echovirus 23 and its relationship to echovirus 22 and other human enteroviruses. Virus Res (1998) 1.74
Parechoviruses. J Virol (1999) 1.66
Polymerase chain reaction amplification of rhinovirus nucleic acids from clinical material. Nucleic Acids Res (1988) 1.63
Molecular epidemiology and evolution of coxsackievirus A9. J Gen Virol (2000) 1.44
Entry of human parechovirus 1. J Virol (2001) 1.39
Systematic replacement of amino acid residues within an Arg-Gly-Asp-containing loop of foot-and-mouth disease virus and effect on cell recognition. J Biol Chem (1996) 1.33
Cell receptors for picornaviruses as determinants of cell tropism and pathogenesis. Trends Microbiol (1998) 1.32
Cell recognition by foot-and-mouth disease virus that lacks the RGD integrin-binding motif: flexibility in aphthovirus receptor usage. J Virol (2000) 1.32
The nucleotide sequences of wild-type coxsackievirus A9 strains imply that an RGD motif in VP1 is functionally significant. J Gen Virol (1992) 1.30
Antigenic properties of human parechovirus 1. J Gen Virol (2000) 1.27
Receptor binding site-deleted foot-and-mouth disease (FMD) virus protects cattle from FMD. J Virol (1995) 1.23
Rapid selection in modified BHK-21 cells of a foot-and-mouth disease virus variant showing alterations in cell tropism. J Virol (1998) 1.21
Animal-derived antigenic variants of foot-and-mouth disease virus type A12 have low affinity for cells in culture. J Virol (1994) 1.21
The coxsackievirus A9 RGD motif is not essential for virus viability. J Virol (1995) 1.20
Cell-surface interactions of echovirus 22. J Biol Chem (1997) 1.18
Human parechovirus 1 utilizes integrins alphavbeta3 and alphavbeta1 as receptors. J Virol (2000) 1.16
Role for beta2-microglobulin in echovirus infection of rhabdomyosarcoma cells. J Virol (1998) 1.11
Foot-and-mouth disease virus is a ligand for the high-affinity binding conformation of integrin alpha5beta1: influence of the leucine residue within the RGDL motif on selectivity of integrin binding. J Gen Virol (2000) 1.06
Point mutations within the betaG-betaH loop of foot-and-mouth disease virus O1K affect virus attachment to target cells. J Virol (1997) 1.06
Molecular cloning and sequence determination of the complete genome of the virulent echovirus 9 strain barty. Virus Genes (1996) 1.06
Integrin alpha(v)beta3 (vitronectin receptor) is a candidate receptor for the virulent echovirus 9 strain Barty. J Gen Virol (1999) 1.04
Involvement of beta2-microglobulin and integrin alphavbeta3 molecules in the coxsackievirus A9 infectious cycle. J Gen Virol (1999) 1.04
Cell attachment and mouse virulence of echovirus 9 correlate with an RGD motif in the capsid protein VP1. Virology (1997) 1.01
In vivo and in vitro identification of structural and sequence elements of the human parechovirus 5' untranslated region required for internal initiation. J Virol (2000) 1.00
High-efficiency utilization of the bovine integrin alpha(v)beta(3) as a receptor for foot-and-mouth disease virus is dependent on the bovine beta(3) subunit. J Virol (2000) 0.98
Detection and characterization of foot-and-mouth disease virus in sub-Saharan Africa. Onderstepoort J Vet Res (1998) 0.94
Complete nucleotide sequence and biological properties of an infectious clone of prototype echovirus 9. Virus Res (1995) 0.93
Biology of coxsackie A viruses. Adv Virus Res (1993) 0.87
Nucleotide sequence of the P1 region of serotype Asia1 foot-and-mouth disease virus. Virus Genes (1994) 0.78
Nucleotide sequence of the structural protein-encoding region of foot-and-mouth disease virus A22-India. Virus Genes (2000) 0.77
Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature (1985) 6.01
The nucleotide sequence of poliovirus type 3 leon 12 a1b: comparison with poliovirus type 1. Nucleic Acids Res (1983) 4.06
Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b. Proc Natl Acad Sci U S A (1984) 3.98
The complete nucleotide sequence of a common cold virus: human rhinovirus 14. Nucleic Acids Res (1984) 3.85
Location and primary structure of a major antigenic site for poliovirus neutralization. Nature (1983) 3.64
An oral preparation to release drugs in the human colon. Br J Clin Pharmacol (1982) 3.49
A distinct picornavirus group identified by sequence analysis. Proc Natl Acad Sci U S A (1992) 3.28
Detection and differentiation of picornaviruses in clinical samples following genomic amplification. J Gen Virol (1990) 2.77
The nucleotide sequence of coxsackievirus A9; implications for receptor binding and enterovirus classification. J Gen Virol (1989) 2.52
Amplification of rhinovirus specific nucleic acids from clinical samples using the polymerase chain reaction. J Med Virol (1989) 2.47
Genetic and phylogenetic clustering of enteroviruses. J Gen Virol (1996) 2.31
Molecular and biological characteristics of echovirus 22, a representative of a new picornavirus group. J Virol (1994) 2.27
Classification of enteroviruses based on molecular and biological properties. J Gen Virol (1997) 2.16
Molecular analysis of coxsackievirus A16 reveals a new genetic group of enteroviruses. Virology (1994) 2.13
The 2A proteins of three diverse picornaviruses are related to each other and to the H-rev107 family of proteins involved in the control of cell proliferation. J Gen Virol (2000) 1.96
RGD-dependent entry of coxsackievirus A9 into host cells and its bypass after cleavage of VP1 protein by intestinal proteases. J Virol (1991) 1.91
Molecular analysis of human parechovirus type 2 (formerly echovirus 23). J Gen Virol (1998) 1.84
Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res (1984) 1.71
The complete nucleotide sequence of coxsackievirus A21. J Gen Virol (1989) 1.70
An RNA tertiary structure in the 3' untranslated region of enteroviruses is necessary for efficient replication. J Virol (1997) 1.67
The nucleotide sequence of human rhinovirus 1B: molecular relationships within the rhinovirus genus. J Gen Virol (1988) 1.67
The complete nucleotide sequence of enterovirus type 70: relationships with other members of the picornaviridae. J Gen Virol (1990) 1.64
Polymerase chain reaction amplification of rhinovirus nucleic acids from clinical material. Nucleic Acids Res (1988) 1.63
Molecular relationships between 21 human rhinovirus serotypes. J Gen Virol (1995) 1.50
Poliovirus type 3: molecular cloning of the genome and nucleotide sequence of the region encoding the protease and polymerase proteins. Nucleic Acids Res (1983) 1.43
The crystal structure of coxsackievirus A9: new insights into the uncoating mechanisms of enteroviruses. Structure (1999) 1.43
Gold-induced neuroencephalopathy responding to dimercaprol. Lancet (1991) 1.42
A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results. J Neurol Neurosurg Psychiatry (1987) 1.42
Adenosine inhibits and potentiates IgE-dependent histamine release from human lung mast cells by an A2-purinoceptor mediated mechanism. Biochem Pharmacol (1984) 1.38
Construction of poliovirus intertypic recombinants by use of cDNA. J Virol (1986) 1.38
Acute transverse myelitis and Guillain-Barré overlap syndrome with serological evidence for mumps viraemia. Acta Neurol Scand (2001) 1.38
The nucleotide sequences of wild-type coxsackievirus A9 strains imply that an RGD motif in VP1 is functionally significant. J Gen Virol (1992) 1.30
Adenosine inhibits and potentiates IgE-dependent histamine release from human basophils by an A2-receptor mediated mechanism. Br J Pharmacol (1983) 1.29
New poliovirus vaccines: a molecular approach. Vaccine (1984) 1.28
Molecular cloning of the genomes of poliovirus type 3 strains by the cDNA: RNA hybrid method. Arch Virol (1984) 1.22
The coxsackievirus A9 RGD motif is not essential for virus viability. J Virol (1995) 1.20
Genetic diversity of enterovirus subgroups. Arch Virol (1989) 1.18
Nucleic acid sequence of the region of the genome encoding capsid protein VP1 of neurovirulent and attenuated type 3 polioviruses. Eur J Biochem (1983) 1.18
Purification of an inositol (1,3,4,5)-tetrakisphosphate 3-phosphatase activity from rat liver and the evaluation of its substrate specificity. J Biol Chem (1991) 1.15
Inositol hexakisphosphate in Schizosaccharomyces pombe: synthesis from Ins(1,4,5)P3 and osmotic regulation. Biochem J (1998) 1.15
The genome of echovirus 11. Virus Res (1995) 1.14
Peripheral blood lymphocyte sub-populations and multiple sclerosis. J Neuroimmunol (1984) 1.13
The relationship between cyclic AMP changes and histamine release from basophil-rich human leucocytes. Biochem Pharmacol (1983) 1.12
The nucleotide sequence of a type 3 poliovirus isolated during a recent outbreak of poliomyelitis in Finland. J Gen Virol (1986) 1.11
Adenosine potentiates immunological histamine release from rat mast cells by a novel cyclic AMP-independent cell-surface action. Br J Pharmacol (1985) 1.10
Widespread recombination within human parechoviruses: analysis of temporal dynamics and constraints. J Gen Virol (2008) 1.08
Studies on the receptor mediating cyclic AMP-independent enhancement by adenosine of IgE-dependent mediator release from rat mast cells. Br J Pharmacol (1986) 1.07
Nucleic acid sequence relationships between enterovirus serotypes. Mol Cell Probes (1987) 1.05
Phytoestrogens are potent inhibitors of estrogen sulfation: implications for breast cancer risk and treatment. J Clin Endocrinol Metab (2004) 1.04
Involvement of beta2-microglobulin and integrin alphavbeta3 molecules in the coxsackievirus A9 infectious cycle. J Gen Virol (1999) 1.04
Sequences in the 5' non-coding region of human rhinovirus 14 RNA that affect in vitro translation. J Gen Virol (1989) 1.04
Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. J Bone Joint Surg Am (2005) 1.02
In vivo and in vitro identification of structural and sequence elements of the human parechovirus 5' untranslated region required for internal initiation. J Virol (2000) 1.00
Comprehensive full-length sequence analyses of human parechoviruses: diversity and recombination. J Gen Virol (2009) 1.00
In vitro studies of fretting corrosion of orthopaedic materials. J Orthop Res (1988) 0.98
Septic arthritis or transient synovitis of the hip in children: the value of clinical prediction algorithms. J Bone Joint Surg Br (2010) 0.96
Pathogenetic differences between coxsackie A and B virus infections in newborn mice. Virus Res (1993) 0.96
Purification and characterization of inositol-1,3,4-trisphosphate 5/6-kinase from rat liver using an inositol hexakisphosphate affinity column. J Biol Chem (1992) 0.95
Radioimmunolocalization of tumours by external scintigraphy after administration of 131I antibody to human chorionic gonadotrophin: preliminary communication. J R Soc Med (1980) 0.94
T'ai Chi Chih as an intervention for heart failure. Nurs Clin North Am (2000) 0.92
The range of the Oxford Shoulder Score in the asymptomatic population: a marker for post-operative improvement. Ann R Coll Surg Engl (2011) 0.92
Detection of enteroviruses using cDNA and synthetic oligonucleotide probes. J Virol Methods (1989) 0.92
Rhinovirus detection using probes from the 5' and 3' end of the genome. Arch Virol (1989) 0.90
Sequence, exon-intron organization, transcription and mutational analysis of prnA, the gene encoding the transcriptional activator of the prn gene cluster in Aspergillus nidulans. Mol Microbiol (1998) 0.90
Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function--some preliminary results. J Antimicrob Chemother (1984) 0.89
Disease incidence and results of extremity lesion treatment: mersey region soft tissue sarcomas (1975-1985). Sarcoma (1998) 0.88
Biology of coxsackie A viruses. Adv Virus Res (1993) 0.87
The effect of three finishing systems on four esthetic restorative materials. Oper Dent (1998) 0.86
Postobstructive pulmonary oedema. Anaesth Intensive Care (2001) 0.86
Do dietary phytoestrogens influence susceptibility to hormone-dependent cancer by disrupting the metabolism of endogenous oestrogens? Biochem Soc Trans (2001) 0.86
Suppressor T cells in family members of patients with multiple sclerosis. Brain (1986) 0.86
The interaction of lithium ions with inositol lipid signalling systems. Biochem Soc Trans (1987) 0.86
A reliable RT-PCR/RFLP assay for the molecular classification of enterovirus reference and wild type strains to either of the two genetic clusters on the basis of 5'-UTR. Mol Cell Probes (2002) 0.83
Molecular detection and identification of an enterovirus during an outbreak of aseptic meningitis. J Clin Lab Anal (2001) 0.83
Ebstein's anomaly: natural and unnatural history. Cleve Clin J Med (1989) 0.82
Human temporomandibular joint and myofascial pain biochemical profiles: a case-control study. J Oral Rehabil (2012) 0.82
Psychological distress of cancer and clinical trial participation: a review of the literature. Eur J Cancer Care (Engl) (2002) 0.82
Separate purinoceptors mediate enhancement by adenosine of concanavalin A-induced mediator release and the cyclic AMP response in rat mast cells. Agents Actions (1986) 0.82
Rat testicular myoid cells express vasopressin receptors: receptor structure, signal transduction, and developmental regulation. Endocrinology (1995) 0.81
Comparison of heat shock response in Brucella abortus and Brucella melitensis. Pak J Biol Sci (2008) 0.81
A clinical and genetic study of a manifesting heterozygote with X-linked myotubular myopathy. Neuromuscul Disord (2000) 0.81
A novel method of typing rhinoviruses using the product of a polymerase chain reaction. Arch Virol (1990) 0.80
Inositol lipid-mediated signalling in response to endothelin and ATP in the mammalian testis. Mol Cell Biochem (1996) 0.80
Site-saturation mutagenesis of the PALTAVETG motif in coxsackievirus A9 capsid protein VP1 reveals evidence of conservation of a periodic hydrophobicity profile. J Gen Virol (1999) 0.80
Sulfation of "estrogenic" alkylphenols and 17beta-estradiol by human platelet phenol sulfotransferases. J Biol Chem (2000) 0.79
Identification and characterization of inositol 1,4,5-trisphosphate receptors in rat testis. Cell Calcium (1997) 0.79
The clinical significance of intrapulmonary vascular dilations in liver transplant candidates. Clin Transplant (2012) 0.79